1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer's Xeljanz Is First JAK Positive In PsA But Challenges Ahead

 
• By Ines Mihel and Christina Vasiliou

Pfizer’s oral JAK inhibitor Xeljanz is set to lead the JAK inhibitors to market in psoriatic arthritis following positive Phase III data particularly in joint inflammation, but skin findings were disappointing.

Rheumatologists suggested Pfizer Inc.'s Xeljanz (tofacitinib) will be a suitable treatment option for patients with heavy joint involvement and minimal skin disease, or patients not concerned about their skin symptoms, after Pfizer unveiled pivotal Phase III data from the OPAL BEYOND and OPAL BROADEN studies in psoriatic arthritis (PsA) at the recent European League Against Rheumatism (EULAR) meeting in Madrid, Spain.

Xeljanz is expected to be the first-in-class JAK inhibitor in PsA. In May, the FDA accepted for review a supplemental...

More from Clinical Trials

2025’s Biggest Launches – Half-Year Progress Report

 
• By Andrew McConaghie

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

More from R&D

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 
• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.